Trials / Completed
CompletedNCT01840449
Somatuline Predictive Factors in Acromegaly and NET
Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 156 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatuline Autogel® 60, 90 or 120 mg |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2016-07-01
- Completion
- 2017-05-01
- First posted
- 2013-04-25
- Last updated
- 2019-01-14
Locations
3 sites across 3 countries: Austria, Germany, Switzerland
Source: ClinicalTrials.gov record NCT01840449. Inclusion in this directory is not an endorsement.